16:35 , Dec 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Parkinson’s disease (PD) Mouse and cell culture studies suggest promoting the expression of SRXN1 , which denitrosylates PRDX2 , could help treat PD. In brain tissue samples from a model of chemical-induced PD, levels...
07:00 , Sep 1, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Peroxiredoxin 6 (PRDX6); microRNA 371-3p (miR-371-3p)

Cancer INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest promoting expression of miR-371-3p or inhibiting PRDX6 could help treat Tarceva erlotinib-resistant lung and other cancers. In patients with lung, colorectal, gastric or...
07:00 , Jul 25, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Peroxiredoxin 2 (PRDX2) Mouse studies suggest compounds that mimic PRDX2 activity could help prevent melanoma metastasis. In mice, melanoma cells pretreated with Prx2-targeting small...
07:00 , May 7, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer HER2 (ERBB2; neu); peroxiredoxin 1 (PRDX1); phosphatase and tensin homolog deleted on chromosome ten (PTEN; MMAC1; TEP1) A study in...